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Abstract 
Objective: The main objective of this study was to detect the presence of 14 respiratory viruses and atypical bacte‑
ria (Mycoplasma pneumoniae, Chlamydia pneumoniae), via polymerase chain reaction in patients under 18 years old 
hospitalized due to community‑acquired pneumonia (CAP) from Lima, Peru.
Results: Atypical pathogens were detected in 40% (58/146); viral etiologies in 36% (52/146) and coinfections in 19% 
(27/146). The most common etiological agent was M. pneumoniae (n = 47), followed by C. pneumoniae (n = 11). The 
most frequent respiratory viruses detected were: respiratory syncytial virus A (n = 35), influenza virus C (n = 21) and 
parainfluenza virus (n = 10). Viral‑bacterial and bacterium‑bacterium coinfections were found in 27 cases. In our study 
population, atypical bacteria (40%) were detected as frequently as respiratory viruses (36%). The presence of M. pneu-
moniae and C. pneumoniae should not be underestimated as they can be commonly isolated in Peruvian children 
with CAP.
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Introduction
Community-acquired pneumonia (CAP) is defined as an 
acute infection within the lungs diagnosed by clinical fea-
tures and lung imaging in a previously healthy person due 
to an infection acquired outside of a healthcare setting 
[1]. This illness is the leading cause of death worldwide 
among children under 5 years old, representing 2 million 
deaths per year [2, 3]. According to the British Thoracic 
Society, the clinical features associated with CAP within 
this age group include fever, tachypnea, breathlessness, 
cough, wheeze or chest pain [4].
In developing countries, the etiological data from chil-
dren with CAP were obtained from reports between 
1980 and 1990 that mainly used serological methods [5] 
and also some low-level evidence descriptive studies [4, 
6]. Most of the studies describing the causative agent of 
CAP in children are limited by the low yield of cultures, 
the difficulty of obtaining adequate sputum specimens 
and the reluctance to perform lung aspirations and bron-
choalveolar lavages in this population [4].
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The main objective of this study was to detect the 
presence of 14 respiratory viruses and atypical bacteria 
(Mycoplasma pneumoniae, Chlamydia pneumoniae) in 
patients under 18 years old hospitalized due to CAP from 
Lima, Peru.
Main text
Materials and methods
Patients and study design
A consecutive cross-sectional study was conducted in 
patients under 18  years of age, admitted to Hospital 
Cayetano Heredia in Lima-Peru with the diagnosis of 
community acquired pneumonia (CAP). Patients who 
fulfilled the selection criteria were studied from January 
2009 to December 2010.
Inclusion criteria Patients who were hospitalized in the 
pediatrics wards with the diagnosis of CAP during the 
study period.
Exclusion criteria Patients who were diagnosed with 
pneumonia 48–72  h after being admitted. Patients who 
were admitted to the ICU service with the diagnosis of 
pneumonia or severe pneumonia. Patients who were 
transferred from other hospitals to the pediatrics wards 
with the diagnosis of pneumonia.
For each patient, a questionnaire with clinical and epi-
demiological features was completed by the physician 
who admitted the patient. The questionnaire applied was 
designed by the government for pneumonia surveillance 
and includes the following information: age, gender and 
relevant clinical information (onset, fever higher than 
38 °C, cough, headache, ear pain, photophobia, conjunc-
tival congestion, rhinorrhea, wheezing, expectoration, 
pharyngeal congestion, sore throat, malaise, abdomi-
nal pain, nausea, vomiting, diarrhea, lymphadenopathy, 
fatigue, arthralgias and myalgias).
Ethics statement
This study has been approved by two independent Eth-
ics Committees from Hospital Cayetano Heredia and 
Instituto de Investigación Nutricional. All samples were 
analyzed after a written informed consent was signed by 
parents or children’s caregivers.
Samples
Nasopharyngeal samples were obtained by inserting a 
swab into both nostrils parallel to the palate (Mini-Tip 
Culture Direct, Becton-Dickinson Microbiology System, 
MD 21152, USA) and a second swab from the posterior 
pharyngeal and tonsillar areas (Viral Culturette, Bec-
ton-Dickinson Microbiology Systems, MD, USA). Both 
nasal and pharyngeal swabs were placed into the same 
tube containing viral transport medium (minimal essen-
tial medium with 2% fetal bovine serum, amphotericin 
B 20  μg/ml, neomycin 40  μg/ml,). Two aliquots of each 
fresh specimen were stored at –  20  °C to be later ana-
lyzed for respiratory viruses and atypical bacteria.
Reverse transcription polymerase chain reaction (RT‑PCR) 
for the analysis of respiratory viruses
For the multiplex RT-PCR, viral genomic RNA and DNA 
were extracted from a total volume of 200 µl of sample by 
the guanidinium thiocyanate extraction method [7]. The 
lysis buffer included 500 molecules of the cloned ampli-
fied product used as internal control in each reaction 
tube and then excluded false negative results due to non-
specific inhibitors or extraction failure. Two independent 
multiplex reverse transcription nested RT-PCR assays able 
to detect from 1 to 10 copies of viral genomes were per-
formed [8, 9]. One nested RT-PCR was performed using 
specific primers for influenza viruses (Flu-A, Flu-B and 
Flu-C), respiratory syncytial viruses (RSV-A and RSV-
B) and adenovirus (ADV). Another, nested RT-PCR was 
prepared with specific primers for detection of human 
parainfluenza viruses (PIV-1, PIV-2, PIV-3 and PIV-4), 
corona viruses (CoV-229E and CoV-OC43), human rhi-
noviruses (HRV), and enteroviruses (HEV). For the PCR, 
a single step combined RT-PCR amplification reaction, 
henceforth called multiplex assay 2, was performed as 
described previously [8, 9] (Additional file 1).
Polymerase chain reaction (PCR) for the analysis 
of Mycoplasma pneumoniae and Chlamydia pneumoniae
Polymerase chain reaction (PCR) was performed with 
5  μl of template DNA, polymerase (GoTaq; Promega, 
Madison, Wisconsin, USA). For M. pneumoniae, the 
primers: Myco-f 5′-GAA GCT TAT GGT ACA GGT 
TGG-3′ and Mico-r 5-ATT ACC ATC CTT GTT GTA 
AGG-3′ were used; and for C. pneumoniae, we used 
primers: Clam-1f-5′-TGC ATA ACC TAC GGT GTG 
TT-3′ and Clam-1r 5′-TGC ATA ACC TAC GGT GTG 
TT-3′, Clam-2f-5′-AGT TGA GCA TAT TCG TGA 
TT-3′ and Clam-2r 5′-TTT ATT CCG TGT CGT CCA 
G-3′. The PCR consisted of initial incubation at 95 °C for 
2 min, followed by 40 cycles of 95 °C for 30 s; 58 °C for 
30 s, and 72 °C for 30 s; with a final extension at 72 °C for 
5  min. Amplicons were detected as 275 and 225 for M. 
pneumoniae and C. pneumoniae respectively base pair 
bands after gel electrophoresis and nucleic acid staining 
(SybrGreen, Promega).
In each PCR assay, negative (transport medium) and 
positive control (cDNA) were prepared with the same 
procedure. Amplified products were recovered from the 
gel, purified (SpinPrep Gel DNA Kit; San Diego, CA) and 
sent for commercial sequencing (Macrogen, Korea).
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Statistical analysis
Qualitative variables were reported as frequencies and 
percentages.
Results
A total of 146 patients under 18  years old hospitalized 
with the diagnosis of CAP were studied. Most patients 
were infants under 1-year-old (81.51%) followed by chil-
dren between 2 and 5 years old (11.64%). The most fre-
quent symptoms were cough (86.96%), fever (79.45%), 
rhinorrhea (76.71%), and pharyngeal congestion (21.92%) 
(Table 1).
Atypical pathogens were detected in n  =  58/146 
(39.72%) cases, respiratory viruses in n = 52/146 (35.62%) 
and coinfections in n  =  27/146 (18.49%) samples; we 
were unable to isolate pathogens in 36 (24.66%) sam-
ples. M. pneumonia and RSV-A were the most common 
etiologies detected in 32.19% and 23.97% respectively, 
followed by C. pneumoniae (7.53%) (Table 2).
Coinfections were detected in 27 cases (18.49%), and 
the most frequent association corresponded to M. pneu-
moniae with VRS-A (9.59%). No viral-viral associations 
were observed (Table 2).
A monthly distribution of the CAP cases was analyzed 
according to their etiologies during the study period. 
An even distribution of infections with C. pneumoniae 
were observed across the year and a relative increase of 
M. pneumoniae was observed from March to June. An 
isolated peak of respiratory viruses was detected during 
March being RSV-A the most common isolated virus 
(Fig. 1).
Discussion
Establishing the etiology of CAP in children can be chal-
lenging in developing countries due to many factors 
including: the difficulty to obtain adequate samples, the 
Table 1 Clinical summaries of pediatric patients with CAP
Others (< 2% of cases: Ear pain, photophobia, conjunctival congestion, 
abdominal pain, lymphadenopathy, fatigue, myalgia)
Frequency
n =  cases
Prevalence (%)
Children
 Age (range)
  0–1 119 81.51
  2–5 17 11.64
  6–10 5 3.42
  > 10 2 1.37
  NR 3 2.05
 Gender
  Male 87 59.59
  Women 59 40.41
  NR 0 0
 Hospitalized 137 93.84
  Sample
   Nasopharyngeal swab 145 99.32
   Nasal swab 1 0.68
   Nasopharyngeal aspired 0 0
Clinical symptoms
 Cough 127 86.99
 Fever 116 79.45
 Rhinorrhea 112 76.71
 Wheezing 73 50
 Expectoration 60 41.01
 Pharyngeal congestion 32 21.92
 Sore throat 19 13‑01
 Malaise 14 9.59
 Vomiting 10 6.85
 Diarrhea 9 6.16
 Lymphadenopathy 3 2.05
 Asthenia 3 2.05
Table 2 Etiological diagnosis of CAP by PCR
Pathogen Frequency
(n = 146)
Prevalence (%)
Atypical pathogens (Group 1) 58 39.72
 Mycoplasma pneumoniae 47 32.19
 Chlamydia pneumoniae 11 7.53
Virus (Group 2) 52 35.62
 RSV‑A 35 23.97
 Flu‑A 3 2.05
 Flu‑C 1 0.68
 CoV 1 0.68
 HRV 1 0.68
 PIV‑1 3 2.05
 PIV‑2 4 2.74
 PIV‑4 3 2.05
 HEV 1 0.68
Coinfections (Group 3) 27 18.49
 Mycoplasma pneumoniae + RSV‑A 14 9.59
 Mycoplasma pneumoniae + HRV 1 0.68
 Mycoplasma pneumoniae + PIV‑1 1 0.68
 Mycoplasma pneumoniae + PIV‑2 1 0.68
 Mycoplasma pneumo-
niae + RSV‑A + HEV
1 0.68
 Mycoplasma pneumoniae + Chlamydia 
pneumoniae + RSV‑A
1 0.68
 Mycoplasma pneumoniae + Chlamydia 
pneumoniae + Flu‑A + Flu‑C
1 0.68
 Chlamydia pneumoniae + RSV‑A 2 1.37
 Chlamydia pneumoniae + CoV 1 0.68
 Chlamydia pneumoniae + Mycoplasma 
pneumoniae
3 2.06
 Chlamydia pneumoniae + Flu‑A 1 0.68
Negative samples 36 24.66
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invasive characteristic of specific diagnostic tests and the 
unavailability of reliable diagnostic methods in the primary 
care setting. Without a sensitive and specific diagnostic 
method, physicians have to rely on clinical criteria based 
on signs and symptoms and epidemiological information 
of CAP to determine the possible causative agent and pro-
vide the patient with the proper treatment [2, 4, 6, 10].
Multiple studies have previously reported that respira-
tory viruses are the leading cause of community acquired 
pneumonia in children and can be detected in more than 
50% of the cases [6, 11]. However, this results may vary 
between studies due to the differences in seasonal pat-
terns observed in distinct areas [4, 6, 10, 12]. In our study 
population, atypical bacteria were slightly more frequently 
detected (39.73%) than respiratory viruses (35.62%).
In the group of patients with pneumonia caused by 
atypical pathogens, M. pneumoniae was the predomi-
nant microorganism and was detected in 32.19% of the 
samples. This finding correlates with some previous stud-
ies that have detected M. pneumoniae in up to 36% of 
children with community acquired pneumonia [4, 13]. 
Moreover, we observed a similar M. pneumoniae pre-
dominance in a previous study we conducted in children 
with acute respiratory illness (ARI) around the same 
study period. We found that in children with ARI, M. 
pneumoniae was present in up to 25% (170/675) of sam-
ples and C. pneumoniae in 10% (71/65) [14].
The most common pathogen isolated within the 
group of patients with viral pneumonia was RSV type 
A (23.97%), followed by Parainfluenza 2 (2.74%). Other 
studies have reported a similar distribution of viral eti-
ologies in children with CAP [4, 7, 11]. However, seasonal 
pattern variations and viral outbreaks can considerably 
alter the prevalence of certain viruses between surveil-
lance studies, especially for RSV and influenza virus [12].
In our series, we observed Chlamydia pneumonia 
infections evenly distributed through the year, whereas 
a relative increase of M. pneumoniae was observed 
from March to June. However, no clear seasonal pat-
tern can be concluded for both atypical bacteria or res-
piratory viruses during our study period, probably due 
to the limited number of cases. Nevertheless, our study 
demonstrates the constant presence of atypical bacteria 
throughout the year in patients with CAP.
In recent years, there has been an increasing interest 
regarding the association between bacteria and viruses 
in the pathogenesis of pneumonia. Studies have shown 
patients that had a viral infection followed by a secondary 
bacterial lower respiratory infection, had a higher mor-
bidity and mortality [15, 16]. Coinfections between bac-
terial and viral isolates have been detected in up to 45% 
of pediatric patients with CAP; and the most common 
association has been reported to be between Streptococ-
cus pneumoniae and respiratory viruses [16]. However, 
M. pneumoniae has also been described as a bacterium 
commonly isolated in sputum samples from young chil-
dren with coinfections. Moreover, it has been proposed 
that patients infected with M. pneumoniae may be more 
susceptible to other infectious pathogens [17]. In our 
study, coinfections between M. pneumoniae and other 
microorganisms were observed in 15.73% of the samples, 
and RSV was the most frequent co-infective agent pre-
sent in 9.59% of samples.
Several studies have demonstrated that the detection of 
viruses in children with CAP has been underestimated, 
primarily due to limited diagnostic methods and difficult 
Fig. 1 Community acquired pneumonia seasonal distribution
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sample collection [4, 15]. In this study, Nested RT-PCR 
was used to simultaneously detect a wide variety of 
viruses with a high sensitivity [8]. Furthermore, a rapid 
extraction method of genomic material was employed, 
allowing a more efficient recognition of viral RNA and 
even bacterial DNA.
In conclusion, our study revealed that both atypical 
bacteria and respiratory viruses are among the most fre-
quent agents detected in children with CAP from Lima, 
Peru. The incorporation of highly sensitive and spe-
cific molecular techniques, such as RT-PCR [4], should 
be considered in order to achieve an accurate etiologi-
cal diagnosis and therapeutic management, avoiding 
the empirical use of antibiotic therapy, particularly in 
children with pneumonia of viral etiology. In addition, 
an increase in macrolide resistance has been observed 
worldwide among CAP patients infected with S. pneumo-
niae and M. pneumoniae. This highlights the importance 
of a precise etiological diagnosis during the management 
of CAP in children [18].
A timely pathogen identification can prevent nosoco-
mial spread of the disease and provide epidemiological 
information to healthcare networks [19], as well as pro-
vide key data to reduce the inappropriate use of antibi-
otics [20]. Antibiotic choice for CAP can vary widely 
across practices and an increasing use of broad-spectrum 
antibiotics have been observed by clinicians at suburban 
practices. In addition, factors not related to the micro-
biologic etiology such as age, previous antibiotic receipt 
or type of insurance are common arbitrary criteria used 
for antibiotic choice increasing the risk for drug resist-
ance [21]. Further investigations should be conducted in 
Peru to have a better understanding of the role of atypical 
agents in CAP and the risks for antibiotic resistance.
Limitations
Our results have shown that RT-PCR is a more efficient 
diagnostic technique since it can detect multiple viruses 
that are not recognized by conventional methods. Nev-
ertheless, despite the improvement in the etiological 
diagnosis of CAP in children, we could not identify an 
etiology in a significant proportion of patients. In those 
cases, S. pneumoniae could be the causative pathogen as 
it is the main cause of pneumonia in most age groups. 
However, we cannot rule out the presence of other etio-
logical agents.
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